Table 1.
Seroprevalence of SARS-CoV-2 by wave and location (95 % credible interval).
| Number of participants | Number of participants positive for SARS-CoV-2 spike protein specific IgG antibodies | Estimated posterior average seroprevalence per 105 people (95 % credible interval | Estimated posterior average prevalence per 105 people (95 % credible interval) | |
|---|---|---|---|---|
| Overall | ||||
| MSD1 | 1998 | 88 | 4702 (2330, 7074) | 78 (1, 155) |
| MSD2 | 1063 | 70 | 6253 (3400, 9105) | 136 (18, 254) |
| MSD3–5 | 621 | 31 | 6231 (3113, 9348) | 174 (14, 334) |
| Other | 35 | 3 | ||
| Total | 3717 | 192 | 17,186 (12,340, 22,032) | 388 (175, 601) |
| Wave 1 | ||||
| MSD1 | 295 | 10 | 2153 (1651, 2656) | 16 (1,31) |
| MSD2 | 121 | 3 | 2230 (1691, 2769) | 20 (1, 38) |
| MSD3–5 | 88 | 2 | 2210 (1708, 2712) | 12 (0, 24) |
| Other | 2 | 0 | ||
| Total | 506 | 15 | 6593 (5701, 7485) | 48 (21, 75) |
| Wave 2 | ||||
| MSD1 | 935 | 22 | 3240 (2109, 4371) | 51 (2,100) |
| MSD2 | 372 | 15 | 3953 (2151, 5756) | 91 (20, 163) |
| MSD3–5 | 271 | 5 | 3698 (2175, 5221) | 90 (13, 165) |
| Other | 15 | 0 | ||
| Total | 1593 | 42 | 10,891 (8274, 13,508) | 232 (117, 347) |
| Wave 3 | ||||
| MSD1 | 480 | 32 | 4461 (2437, 6485) | 106 (1,211) |
| MSD2 | 342 | 21 | 6003 (3098, 8909) | 192 (38, 346) |
| MSD3–5 | 134 | 3 | 6032 (3120, 8944) | 217 (23, 411) |
| Other | 9 | 1 | ||
| Total | 965 | 57 | 16,496 (11,911, 21,081) | 515 (246, 784) |
| Wave 4 | ||||
| MSD1 | 288 | 24 | 7342 (2720, 11,963) | 119 (0, 238) |
| MSD2 | 228 | 31 | 10,416 (5335, 15,498) | 222 (18, 425) |
| MSD3–5 | 128 | 21 | 10,506 (4591, 16,420) | 332 (19, 645) |
| Other | 9 | 2 | ||
| Total | 653 | 78 | 28,264 (19,200, 37,328) | 673 (281, 1065) |
IgG = immunoglobulin G.